NHKFF yields 557.10% · PFE yields 6.13%● Live data
📍 NHKFF pulled ahead of the other in Year 1
Combined, NHKFF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NHKFF + PFE for your $10,000?
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs. It offers antidiabetic agents, antacids, antireflux agents, beta-blocker, hypnotic and sedative, angiotensin ? antagonist, angiotensin ? antagonist/diuretic combination, dyslipidaemic agent, and calcium antagonist products, as well as chemotherapeutic agents. The company also provides treatments for circulatory, digestive, respiratory, nervous system, allergies, and others. It supplies its products to medical institutions, including hospitals, clinics, dispensing pharmacies, etc. The company was formerly known as Nihon Iyakuhin Kogyo Co., Ltd. and changed its name to Nichi-Iko Pharmaceutical Co., Ltd. in 2005. Nichi-Iko Pharmaceutical Co., Ltd. was incorporated in 1947 and is headquartered in Toyama, Japan.
Full NHKFF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.